Carter Cliff, based in United States, is currently a CEO at Papillon Therapeutics Inc, bringing experience from previous roles at StemCardia, Kenai Therapeutics, Opsis Therapeutics and Vascugen. Carter Cliff holds a 1999 - 2001 Doctor of Philosophy in Molecular Biology @ UT Southwestern Medical Center. With a robust skill set that includes Sales, Immunoassays, Microsoft Office, Drug Discovery, Cell Biology and more, Carter Cliff contributes valuable insights to the industry. Carter Cliff has 6 emails and 1 mobile phone number on RocketReach.